DYNAVAX TECHNOLOGIES news, videos and press releases - Page 3
For more news please use our advanced search feature.
DYNAVAX TECHNOLOGIES - More news...
DYNAVAX TECHNOLOGIES - More news...
- Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman
- Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Present at Upcoming Investment Conferences
-
“The Buzz'' Show: Dynavax Technologies Corp (NASDAQ: DVAX) Positive Clover Covid-19 Trial Data
- COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial
- Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Thinking about buying stock in Skillz, Rigel Pharmaceuticals, Dynavax Technologies, Bellicum Pharmaceuticals, or Baudax Bio?
- Thinking about buying stock in PainReform, Gap, Multiplan, Aterian, or Dynavax Technologies?
- Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant
- Dynavax Announces Second Quarter 2021 Financial Results
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021
- Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
- Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
- Dynavax to Present at the William Blair 41st Annual Growth Stock Conference
- Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering
- Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
- Dynavax Announces First Quarter 2021 Financial Results
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 Annual Conference on Vaccinology Research (ACVR)
- Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
- Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference
